Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while Vanguard Information Technology Index Fund ETF trades at $120.86. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VGT | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | — |
52-Week High | $30.81 | $125.77 |
52-Week Low | $16.87 | $83.59 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VGT, the Vanguard Information Technology ETF, trades at $121.45, up 1.55% on the day, with a strong bullish technical signal from moving averages. The ETF provides concentrated exposure to major U.S. technology stocks, particularly benefiting from the AI infrastructure build-out. Recent institutional buying activity from firms like Bank of America and Baron Financial Group highlights continued confidence.
The outlook for VGT remains positive, driven by secular tech trends and AI investment, though risks include high concentration in top holdings and sector-specific volatility. The ETF's low-cost structure and pure-play tech focus present a compelling opportunity for long-term growth investors, but its performance is heavily tied to the fortunes of a few mega-cap companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
